Acute viral nasopharyngitis cost-effectiveness of therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Cost-Effectiveness of Therapy== | ==Cost-Effectiveness of Therapy== | ||
In the USA alone, the common cold leads to 75 to 100 million physician visits annually at a conservative cost estimate of $7.7 billion per year. Americans spend $2.9 billion on over-the-counter drugs and another $400 million on prescription medicines for symptomatic relief. | In the USA alone, the common cold leads to 75 to 100 million physician visits annually at a conservative cost estimate of $7.7 billion per year. Americans spend $2.9 billion on over-the-counter drugs and another $400 million on prescription medicines for symptomatic relief. | ||
More than one-third of patients who saw a doctor received an antibiotic prescription, which not only contributes to unnecessary costs ($1.1 billion annually on an estimated 41 million antibiotic prescriptions in the United States), but also has implications for antibiotic resistance from overuse of such drugs. | |||
More than one-third of patients who saw a doctor received an antibiotic prescription, which not only contributes to unnecessary costs ($1.1 billion annually on an estimated 41 million antibiotic prescriptions in the United States), but also has implications for antibiotic resistance from overuse of such drugs. | An estimated 22 to 189 million school days are missed annually due to a cold. As a result, parents missed 126 million workdays to stay home to care for their children. When added to the 150 million workdays missed by employees suffering from a cold, the total economic impact of cold-related work loss exceeds $20 billion. | ||
An estimated 22 to 189 million school days are missed annually due to a cold. As a result, parents missed 126 million workdays to stay home to care for their children. When added to the 150 million workdays missed by employees suffering from a cold, the total economic impact of cold-related work loss exceeds $20 billion. | |||
==References== | ==References== | ||
Revision as of 16:58, 21 August 2012
|
Acute viral nasopharyngitis Microchapters |
|
Differentiating acute viral nasopharyngitis from other diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute viral nasopharyngitis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Acute viral nasopharyngitis cost-effectiveness of therapy |
|
FDA on Acute viral nasopharyngitis cost-effectiveness of therapy |
|
CDC on Acute viral nasopharyngitis cost-effectiveness of therapy |
|
Acute viral nasopharyngitis cost-effectiveness of therapy in the news |
|
Blogs onAcute viral nasopharyngitis cost-effectiveness of therapy |
|
Risk calculators and risk factors for Acute viral nasopharyngitis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cost-Effectiveness of Therapy
In the USA alone, the common cold leads to 75 to 100 million physician visits annually at a conservative cost estimate of $7.7 billion per year. Americans spend $2.9 billion on over-the-counter drugs and another $400 million on prescription medicines for symptomatic relief. More than one-third of patients who saw a doctor received an antibiotic prescription, which not only contributes to unnecessary costs ($1.1 billion annually on an estimated 41 million antibiotic prescriptions in the United States), but also has implications for antibiotic resistance from overuse of such drugs. An estimated 22 to 189 million school days are missed annually due to a cold. As a result, parents missed 126 million workdays to stay home to care for their children. When added to the 150 million workdays missed by employees suffering from a cold, the total economic impact of cold-related work loss exceeds $20 billion.